News

Sublingual immunotherapy is coming soon


 

EXPERT ANALYSIS FROM THE PULMONARY AND ALLERGY UPDATE

Dr. Nelson’s prediction that these three SLIT products are headed for FDA approval this spring stems from enthusiastic endorsements by the agency’s Allergenic Products Advisory Committee. The SLIT grass allergy products were recommended unanimously, and the ragweed SLIT also received a strongly favorable vote.

He reported serving as a consultant to Merck, Pearl Therapeutic, and Circassia.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

Pediatric hypertension: Often missed and mismanaged
MDedge Family Medicine
Stroke risk jumps after head, neck trauma
MDedge Family Medicine
VIDEO: Traumatic injury ups stroke risk in people under 50
MDedge Family Medicine
Immunization update: The latest ACIP recommendations
MDedge Family Medicine
VIDEO: Practice pearls improve acne treatment
MDedge Family Medicine
Report highlights state of child abuse and neglect research
MDedge Family Medicine
Sizzle magnets: a worrisome buzz in the emergency department
MDedge Family Medicine
Campus meningitis outbreaks tamed but can our approach last?
MDedge Family Medicine
Omalizumab reduces epinephrine need during oral immunotherapy
MDedge Family Medicine
Foods can still trigger eosinophilic esophagitis after allergy outgrown
MDedge Family Medicine